Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189


Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer.

De Giorgi U, Mego M, Scarpi E, Giordano A, Giuliano M, Valero V, Alvarez RH, Ueno NT, Cristofanilli M, Reuben JM.

Ther Adv Med Oncol. 2019 Aug 14;11:1758835919866065. doi: 10.1177/1758835919866065. eCollection 2019.


Circulating Tumor Cells: State-of-the-art Update on Technologies and Clinical Applications.

Yap K, Cohen EN, Reuben JM, Khoury JD.

Curr Hematol Malig Rep. 2019 Jul 30. doi: 10.1007/s11899-019-00531-x. [Epub ahead of print] Review.


Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer.

Cohen EN, Fouad TM, Lee BN, Arun BK, Liu D, Tin S, Gutierrez Barrera AM, Miura T, Kiyokawa I, Yamashita J, Alvarez RH, Valero V, Woodward WA, Shen Y, Ueno NT, Cristofanilli M, Reuben JM.

Breast Cancer Res Treat. 2019 Aug;176(3):545-556. doi: 10.1007/s10549-019-05258-0. Epub 2019 May 3.


Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.

Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA.

Cancer Immunol Res. 2019 Jun;7(6):1025-1035. doi: 10.1158/2326-6066.CIR-18-0619. Epub 2019 May 1.


Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.

Mego M, Karaba M, Minarik G, Benca J, Silvia J, Sedlackova T, Manasova D, Kalavska K, Pindak D, Cristofanilli M, Reuben JM, Mardiak J.

Anticancer Res. 2019 Apr;39(4):1829-1837. doi: 10.21873/anticanres.13290.


Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.

Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT.

PLoS One. 2018 Oct 12;13(10):e0204513. doi: 10.1371/journal.pone.0204513. eCollection 2018.


Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center.

Fouad TM, Ueno NT, Yu RK, Ensor JE, Alvarez RH, Krishnamurthy S, Lucci A, Reuben JM, Yang W, Willey JS, Valero V, Bondy ML, Cristofinalli M, Shete S, Woodward WA, El-Zein R.

PLoS One. 2018 Sep 24;13(9):e0204372. doi: 10.1371/journal.pone.0204372. eCollection 2018.


Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT.

JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436.


Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer.

Reddy JP, Atkinson RL, Larson R, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton CJ, Bambhroliya A, Reuben JM, Van Laere SJ, Krishnamurthy S, Symmans WF, Brewster AM, Woodward WA.

Breast Cancer Res Treat. 2018 Sep;171(2):283-293. doi: 10.1007/s10549-018-4835-6. Epub 2018 Jun 1.


Author Correction: Inflammatory breast cancer biology: the tumour microenvironment is key.

Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT.

Nat Rev Cancer. 2018 Aug;18(8):526. doi: 10.1038/s41568-018-0022-7.


Inflammatory breast cancer biology: the tumour microenvironment is key.

Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT.

Nat Rev Cancer. 2018 Aug;18(8):485-499. doi: 10.1038/s41568-018-0010-y. Review. Erratum in: Nat Rev Cancer. 2018 May 10;:.


Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.

Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT.

J Cancer. 2017 Oct 9;8(17):3607-3614. doi: 10.7150/jca.21200. eCollection 2017.


Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer.

Alvarez RH, Bechara RI, Naughton MJ, Adachi JA, Reuben JM.

Oncologist. 2018 Jun;23(6):660-669. doi: 10.1634/theoncologist.2017-0343. Epub 2018 Feb 27. Review.


Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer.

Rahal OM, Wolfe AR, Mandal PK, Larson R, Tin S, Jimenez C, Zhang D, Horton J, Reuben JM, McMurray JS, Woodward WA.

Int J Radiat Oncol Biol Phys. 2018 Mar 15;100(4):1034-1043. doi: 10.1016/j.ijrobp.2017.11.043. Epub 2017 Dec 7.


Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer.

Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT.

Oncotarget. 2018 Jan 4;9(6):6872-6882. doi: 10.18632/oncotarget.23914. eCollection 2018 Jan 23.


EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer.

Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA Jr, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT.

Oncotarget. 2017 Jul 4;8(40):67904-67917. doi: 10.18632/oncotarget.18958. eCollection 2017 Sep 15.


Androgen receptor expression on circulating tumor cells in metastatic breast cancer.

Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, Lim B, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT.

PLoS One. 2017 Sep 28;12(9):e0185231. doi: 10.1371/journal.pone.0185231. eCollection 2017.


A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer.

Woodward WA, Fang P, Arriaga L, Gao H, Cohen EN, Reuben JM, Valero V, Le-Petross H, Middleton LP, Babiera GV, Strom EA, Tereffe W, Hoffman K, Smith BD, Buchholz TA, Perkins GH.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):777-783. doi: 10.1016/j.ijrobp.2017.04.030. Epub 2017 May 3. Erratum in: Int J Radiat Oncol Biol Phys. 2018 Jun 1;101(2):497.


Thrombocytosis as a prognostic factor in inflammatory breast cancer.

Harano K, Kogawa T, Wu J, Yuan Y, Cohen EN, Lim B, Reuben JM, Ueno NT.

Breast Cancer Res Treat. 2017 Dec;166(3):819-832. doi: 10.1007/s10549-017-4463-6. Epub 2017 Aug 22.


Novel therapeutic strategies in the treatment of triple-negative breast cancer.

Oualla K, El-Zawahry HM, Arun B, Reuben JM, Woodward WA, Gamal El-Din H, Lim B, Mellas N, Ueno NT, Fouad TM.

Ther Adv Med Oncol. 2017 Jul;9(7):493-511. doi: 10.1177/1758834017711380. Epub 2017 Jun 13. Review.


Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy.

Adams DL, Adams DK, He J, Kalhor N, Zhang M, Xu T, Gao H, Reuben JM, Qiao Y, Komaki R, Liao Z, Edelman MJ, Tang CM, Lin SH.

Clin Cancer Res. 2017 Oct 1;23(19):5948-5958. doi: 10.1158/1078-0432.CCR-17-0802. Epub 2017 Jul 5.


In vitro and in vivo effect of flutamide on steroid hormone secretion in canine and human inflammatory breast cancer cell lines.

Caceres S, Monsalve B, Peña L, de Andres PJ, Alonso-Diez A, Illera MJ, Woodward WA, Reuben JM, Silvan G, Illera JC.

Vet Comp Oncol. 2018 Mar;16(1):148-158. doi: 10.1111/vco.12324. Epub 2017 Jun 6.


Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2-Negative Metastatic Breast Cancer.

Schott AF, Goldstein LJ, Cristofanilli M, Ruffini PA, McCanna S, Reuben JM, Perez RP, Kato G, Wicha M.

Clin Cancer Res. 2017 Sep 15;23(18):5358-5365. doi: 10.1158/1078-0432.CCR-16-2748. Epub 2017 May 24.


Circulating tumor cells and coagulation-Minireview.

Bystricky B, Reuben JM, Mego M.

Crit Rev Oncol Hematol. 2017 Jun;114:33-42. doi: 10.1016/j.critrevonc.2017.04.003. Epub 2017 Apr 6. Review.


4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.

Harao M, Forget MA, Roszik J, Gao H, Babiera GV, Krishnamurthy S, Chacon JA, Li S, Mittendorf EA, DeSnyder SM, Rockwood KF, Bernatchez C, Ueno NT, Radvanyi LG, Vence L, Haymaker C, Reuben JM.

Cancer Immunol Res. 2017 Jun;5(6):439-445. doi: 10.1158/2326-6066.CIR-16-0364. Epub 2017 May 4.


Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression.

Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT.

Breast Cancer Res Treat. 2017 Jul;164(1):57-67. doi: 10.1007/s10549-017-4233-5. Epub 2017 Apr 17.


Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.

Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT.

Lancet Oncol. 2017 Apr;18(4):e228-e232. doi: 10.1016/S1470-2045(17)30192-4. Review.


Identification of frequent somatic mutations in inflammatory breast cancer.

Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT.

Breast Cancer Res Treat. 2017 Jun;163(2):263-272. doi: 10.1007/s10549-017-4165-0. Epub 2017 Feb 27.


A Comprehensive Lifestyle Randomized Clinical Trial: Design and Initial Patient Experience.

Arun B, Austin T, Babiera GV, Basen-Engquist K, Carmack CL, Chaoul A, Cohen L, Connelly L, Haddad R, Harrison C, Li Y, Mallaiah S, Nagarathna R, Parker PA, Perkins GH, Reuben JM, Shih YT, Spelman A, Sood A, Yang P, Yeung SJ.

Integr Cancer Ther. 2017 Mar;16(1):3-20. doi: 10.1177/1534735416679516. Epub 2016 Nov 30.


Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models.

Wolfe AR, Trenton NJ, Debeb BG, Larson R, Ruffell B, Chu K, Hittelman W, Diehl M, Reuben JM, Ueno NT, Woodward WA.

Oncotarget. 2016 Dec 13;7(50):82482-82492. doi: 10.18632/oncotarget.12694.


Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer.

Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Tin S, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM.

Oncotarget. 2017 May 30;8(22):35656-35668. doi: 10.18632/oncotarget.10290.


Circulating Tumor Cells (CTC) Are Associated with Defects in Adaptive Immunity in Patients with Inflammatory Breast Cancer.

Mego M, Gao H, Cohen EN, Anfossi S, Giordano A, Sanda T, Fouad TM, De Giorgi U, Giuliano M, Woodward WA, Alvarez RH, Valero V, Ueno NT, Hortobagyi GN, Cristofanilli M, Reuben JM.

J Cancer. 2016 Jun 3;7(9):1095-104. doi: 10.7150/jca.13098. eCollection 2016.


Expression of SOCS1 and CXCL12 Proteins in Primary Breast Cancer Are Associated with Presence of Circulating Tumor Cells in Peripheral Blood.

Smolkova B, Mego M, Horvathova Kajabova V, Cierna Z, Danihel L, Sedlackova T, Minarik G, Zmetakova I, Krivulcik T, Gronesova P, Karaba M, Benca J, Pindak D, Mardiak J, Reuben JM, Fridrichova I.

Transl Oncol. 2016 Jun;9(3):184-90. doi: 10.1016/j.tranon.2016.03.004. Epub 2016 Apr 25.


Steroid Tumor Environment in Male and Female Mice Model of Canine and Human Inflammatory Breast Cancer.

Caceres S, Peña L, Silvan G, Illera MJ, Woodward WA, Reuben JM, Illera JC.

Biomed Res Int. 2016;2016:8909878. doi: 10.1155/2016/8909878. Epub 2016 Apr 18.


Canine cell line, IPC-366, as a good model for the study of inflammatory breast cancer.

Caceres S, Peña L, Lacerda L, Illera MJ, de Andres PJ, Larson RA, Gao H, Debeb BG, Woodward WA, Reuben JM, Illera JC.

Vet Comp Oncol. 2017 Sep;15(3):980-995. doi: 10.1111/vco.12238. Epub 2016 May 5.


Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism.

Debeb BG, Lacerda L, Larson R, Wolfe AR, Krishnamurthy S, Reuben JM, Ueno NT, Gilcrease M, Woodward WA.

Oncotarget. 2016 May 10;7(19):28329-39. doi: 10.18632/oncotarget.8631.


miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer.

Debeb BG, Lacerda L, Anfossi S, Diagaradjane P, Chu K, Bambhroliya A, Huo L, Wei C, Larson RA, Wolfe AR, Xu W, Smith DL, Li L, Ivan C, Allen PK, Wu W, Calin GA, Krishnamurthy S, Zhang XH, Buchholz TA, Ueno NT, Reuben JM, Woodward WA.

J Natl Cancer Inst. 2016 Apr 13;108(8). doi: 10.1093/jnci/djw026. Print 2016 Aug.


CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer.

Mego M, Cholujova D, Minarik G, Sedlackova T, Gronesova P, Karaba M, Benca J, Cingelova S, Cierna Z, Manasova D, Pindak D, Sufliarsky J, Cristofanilli M, Reuben JM, Mardiak J.

BMC Cancer. 2016 Feb 19;16:127. doi: 10.1186/s12885-016-2143-2.


Inflammatory Breast Cancer: A Distinct Clinicopathological Entity Transcending Histological Distinction.

Raghav K, French JT, Ueno NT, Lei X, Krishnamurthy S, Reuben JM, Valero V, Ibrahim NK.

PLoS One. 2016 Jan 11;11(1):e0145534. doi: 10.1371/journal.pone.0145534. eCollection 2016.


Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics.

Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O'Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A.

Clin Cancer Res. 2016 May 15;22(10):2359-67. doi: 10.1158/1078-0432.CCR-15-2476. Epub 2016 Jan 5.


Steroid hormone secretion in inflammatory breast cancer cell lines.

Illera JC, Caceres S, Peña L, de Andres PJ, Monsalve B, Illera MJ, Woodward WA, Reuben JM, Silvan G.

Horm Mol Biol Clin Investig. 2015 Dec;24(3):137-45. doi: 10.1515/hmbci-2015-0024.


Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.

Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Senti C, Brambilla P, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of European Blood and Marrow Transplantation Society (EBMT).

Tumour Biol. 2015 Sep;36(9):6653-65. doi: 10.1007/s13277-015-3944-7. Epub 2015 Aug 26. Review.


Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.

Shah N, Shi Q, Williams LA, Mendoza TR, Wang XS, Reuben JM, Dougherty PM, Bashir Q, Qazilbash MH, Champlin RE, Cleeland CS, Giralt SA.

Biol Blood Marrow Transplant. 2016 Feb;22(2):226-231. doi: 10.1016/j.bbmt.2015.07.036. Epub 2015 Aug 5.


Detection and enumeration of circulating tumor cells based on their invasive property.

Wang H, Hara Y, Liu X, Reuben JM, Xie Y, Xu H, Bu G, Pei Y, Gupta V, Wu X.

Oncotarget. 2015 Sep 29;6(29):27304-11. doi: 10.18632/oncotarget.4454.


Inflammation Mediated Metastasis: Immune Induced Epithelial-To-Mesenchymal Transition in Inflammatory Breast Cancer Cells.

Cohen EN, Gao H, Anfossi S, Mego M, Reddy NG, Debeb B, Giordano A, Tin S, Wu Q, Garza RJ, Cristofanilli M, Mani SA, Croix DA, Ueno NT, Woodward WA, Luthra R, Krishnamurthy S, Reuben JM.

PLoS One. 2015 Jul 24;10(7):e0132710. doi: 10.1371/journal.pone.0132710. eCollection 2015.


Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.

Mego M, Cierna Z, Janega P, Karaba M, Minarik G, Benca J, Sedlácková T, Sieberova G, Gronesova P, Manasova D, Pindak D, Sufliarsky J, Danihel L, Reuben JM, Mardiak J.

BMC Cancer. 2015 Jul 22;15:533. doi: 10.1186/s12885-015-1548-7.


Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.

Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JD.

Leukemia. 2016 Jan;30(1):242-7. doi: 10.1038/leu.2015.122. Epub 2015 May 15. No abstract available.


Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.

Ravelli A, Reuben JM, Lanza F, Anfossi S, Cappelletti MR, Zanotti L, Gobbi A, Milani M, Spada D, Pedrazzoli P, Martino M, Bottini A, Generali D; Solid Tumor Working Party of the European Blood and Marrow Transplantation Society (EBMT).

Expert Rev Anticancer Ther. 2015 Jun;15(6):689-702. doi: 10.1586/14737140.2015.1042864. Epub 2015 Apr 30. Review.


Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366.

Caceres S, Peña L, de Andres PJ, Illera MJ, Lopez MS, Woodward WA, Reuben JM, Illera JC.

PLoS One. 2015 Mar 25;10(3):e0122277. doi: 10.1371/journal.pone.0122277. eCollection 2015.


Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients.

Mego M, Karaba M, Minarik G, Benca J, Sedlácková T, Tothova L, Vlkova B, Cierna Z, Janega P, Luha J, Gronesova P, Pindak D, Fridrichova I, Celec P, Reuben JM, Cristofanilli M, Mardiak J.

Breast J. 2015 Mar-Apr;21(2):155-60. doi: 10.1111/tbj.12388. Epub 2015 Jan 27.


Supplemental Content

Loading ...
Support Center